CYTK · Cytokinetics, Incorporated
Price
Snapshot
50 fields · last close| Market Cap | $8.84B |
| P/E | — |
| Float | 135.3M |
| Beta | 0.40 |
| Volatility 30D | 28.4% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 78.0 |
| Price | 55.16 |
| Change | −13.27% |
| Prev Close | 63.60 |
| Open | 64.06 |
| Day Low | 60.98 |
| Day High | 64.96 |
| Avg Vol | 1 |
| Avg $ Vol | $84.44M |
| 52W High | 88.31 |
| 52W Low | 58.05 |
| 52W Pos | −9.6% |
| From High | −37.54% |
| From Low | −4.98% |
| Max DD 1Y | −30.40% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −11.70% |
| SMA 50 | −17.22% |
| SMA 200 | −21.28% |
| RSI (14) | 49.5 |
| Vol 90D | 32.2% |
| Vol 1Y | 41.4% |
| 1Y Range | 58–88 |
| Daily bars | 549 |
| Perf Week | +3.79% |
| Perf Month | +3.67% |
| Perf Quarter | −21.84% |
| Perf Half Y | −15.02% |
| Perf Year | +5.95% |
| Perf YTD | −10.64% |
| Prev Day | −13.27% |
| Clavix | B+ |
| Debt / Eq | 0.59 |
| Curr Ratio | 4.53 |
| Int Cover | -10.7× |
| FCF Margin | — |
| Rev Growth | +376.6% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 8 / 35 |
Clavix risk grade
regraded every trading dayCYTK grades B+, 78.0 of 100. Steadiest on News Sentiment (68), most exposed on Price Stability (62, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 8 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CYTK | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.40 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 28.4% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −30.4% | — |
| Typical daily movemedian absolute daily change | 1.48% | — |
| Days beyond ±3%of the last 252 sessions | 51 (20%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CYTK | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.40 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CYTK | |
|---|---|
| 1 week | +3.8% |
| 1 month | +3.7% |
| Year to date | −10.6% |
| 1 year | +5.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CYTK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 10 Sep |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 5 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CYTK | |
|---|---|
| Revenue growthyear over year | +376.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCytokinetics reported a quarterly loss of $1.37 per share, smaller than the Zacks consensus estimate of a $1.50 loss and the $1.54 loss reported a year earlier. The headline says revenue also exceeded estimates, but no revenue figure is provided.
Cytokinetics reported $44.5 million in net product revenue for MYQORZO (aficamten) in the third quarter of 2026 and approximately $1.6 billion in cash, cash equivalents and investments as of September 30, 2026. It expects to submit a supplemental application for non-obstructive hypertrophic cardiomyopathy in Q4 2026 and a European Union application in early 2027.
Wall Street Zen lowered Cytokinetics (NASDAQ: CYTK) from a "Hold" rating to a "Sell" rating in a Tuesday report. The article provides no price target or details about Cytokinetics' finances, operations, or regulatory status.
On October 15, 2026, Cytokinetics granted 29 employees who started in September and October 2026 options to purchase 60,465 common shares and 40,084 restricted stock units, which settle in common shares when vesting conditions are met. The company said the awards were material inducements to employment.
HC Wainwright restated a "Buy" rating and set a $140 target price for Cytokinetics shares. The brief report provides no financial, operational, or regulatory update from which to draw further implications.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals, Inc. | C+ | $8.71B | — | 1.39 | Compare |
| KRYS | Krystal Biotech, Inc. | B | $9.21B | 38.12 | 0.71 | Compare |
| TWST | Twist Bioscience Corporation | D | $9.24B | — | 2.30 | Compare |
| MDGL | Madrigal Pharmaceuticals, Inc. | B | $9.25B | — | -1.03 | Compare |
| PTGX | Protagonist Therapeutics, Inc. | B | $9.28B | 110.85 | 1.21 | Compare |
| CAI | Caris Life Sciences, Inc. | C | $9.39B | 88.30 | 0.41 | Compare |
| TGTX | TG Therapeutics, Inc. | B- | $9.43B | 21.06 | 1.77 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.